CPRX Q2 2024 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$123M+23.2% YoY

Gross Profit

$107M87.4% margin

Operating Income

$54M44.2% margin

Net Income

$41M33.2% margin

EPS (Diluted)

$0.33

QoQ Revenue Growth

+24.6%

Cash Flow

Operating Cash Flow

$64M

Free Cash Flow

$64M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$706M

Total Liabilities

$98M

Stockholders' Equity

$609M

Cash & Equivalents

$376M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$123M	$100M	+23.2%
Gross Profit	$107M	$88M	+22.6%
Operating Income	$54M	$47M	+16.2%
Net Income	$41M	$38M	+8.0%

Revenue Segments

Product Revenue Net

$123M100%

License And Other Revenue

$57,0000%